Clinical research
According to a BioPharma Dive report, since March, more than 100 biopharma companies announced their clinical trials were disrupted in some way because of the pandemic.
The company indicated the initial data was promising, but the data for overall survival benefit and additional secondary endpoints were not yet mature and the trial will continue.
Finch Therapeutics reported positive topline results from PRISM3, its Phase II trial of CP101, an oral microbiome drug for the prevention of recurrent C. difficile infection.
Specifically, the product was examined for its use in subjects where pituitary surgery is not an option or has not be curative.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 19, 2020.
Pfizer and Sangamo Therapeutics released follow-up data from its Phase I/II Alta study in hemophilia A that showed an investigational gene therapy treatment provided blood-clotting activity levels for more than one year.
In a Phase III study, Genentech’s Tecentriq (atezolizumab) in combination with Celgene’s Abraxane followed by chemotherapy demonstrated a statistically significant and clinically meaningful improvement in treating patients with early triple-negative breast cancer.
The company announced it planned to soon start enrolling an open-label, single-arm Phase II/III clinical trial of remdesivir in about 50 pediatric patients with moderate-to-severe COVID-19, including newborns through adolescents.
BioMarin Pharmaceutical released new data today from its previously reported four-year update of the open-label Phase I/II study of valoctocogene roxaparvovec.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 17, 2020.
PRESS RELEASES